Oral Cavity Mucosal Melanoma

subtype

Identifier: CI-CAN-00003484
Entity page: /cancer/oral-cavity-mucosal-melanoma ↗
Edges: 5

Neighbours: 3 drugs2 trials
Drawn: 5 of 5 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Oral Cavity Mucosal Melanoma investigated in trials for …INVESTIGATED_IN_TRIALSderived3 of 3
→ investigated in trials for	Nivolumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Oral Cavity Mucosal Melanoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants

Oral Cavity Mucosal Melanoma studied in …STUDIED_INderived2 of 2
→ studied in	NCT05111574Phase 2 · active not recruiting Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery · condition mapped ONTOLOGY_EXACT · 2 trials mapped (1 active)	—	—	Oral Cavity Mucosal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03220009Phase 2 · withdrawn Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma · condition mapped ONTOLOGY_EXACT · 2 trials mapped (1 active)	—	—	Oral Cavity Mucosal Melanoma	1	Observed	clinicaltrials	graph →

Oral Cavity Mucosal Melanoma studied in …STUDIED_INderived2 of 2

→ studied in

NCT05111574Phase 2 · active not recruiting

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery · condition mapped ONTOLOGY_EXACT · 2 trials mapped (1 active)

—

Oral Cavity Mucosal Melanoma

Observed

clinicaltrials

graph →

→ studied in

NCT03220009Phase 2 · withdrawn

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma · condition mapped ONTOLOGY_EXACT · 2 trials mapped (1 active)

—

Oral Cavity Mucosal Melanoma

Observed

clinicaltrials

graph →

Radial view

Every edge, grouped by relationship

Strongest chains